Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept

Rheumatology

Volumn 48, Issue 2, 2009, Pages 144-148

  Borte, Stephan ^a   Liebert, U G ^a   Borte, M ^a   Sack, U ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cell mediated immunity; Enzyme linked immunospot assay; Etanercept; Juvenile idiopathic arthritis; Measles; Methotrexate; MMR vaccine; Mumps; Rubella

Indexed keywords

ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADOLESCENT; ARTICLE; CASE CONTROL STUDY; CELL STIMULATION; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MALE; MEASLES; MEMORY T LYMPHOCYTE; MONOTHERAPY; MUMPS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVACCINATION; RUBELLA; SEROPREVALENCE;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; INTERFERON-GAMMA; MALE; MEASLES-MUMPS-RUBELLA VACCINE; METHOTREXATE; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58749100481     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken436     Document Type: Article

References (24)

1. Borchers AT, Selmi C, Cheema G, Keen CL, Shoenfeld Y, Gershwin ME. Juvenile idiopathic arthritis. Autoimmun Rev 2006;5:279-98.
2. Jordan A, McDonagh JE. Juvenile idiopathic arthritis: The paediatric perspective. Pediatr Radiol 2006;36:734-42.
3. Davies K, Woo P. British paediatric rheumatology group. Immunization in rheumatic diseases of childhood: An audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology 2002;41:937-41.
4. McCann LJ. Should children under treatment for juvenile idiopathic arthritis receive flu vaccination? Arch Dis Child 2007;92:366-8.
5. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 2007;66: 1384-7.
6. Minden K, Niewerth M, Borte M, Singendonk W, Haas JP. [Impfungen bei rheumatischen Erkrankungen des Kindes- und Jugendalters]. Z Rheumatol 2007;66:111-20.
7. Centers for Disease Control and Prevention (CDC). Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47:1-57.
8. Dhiman N, Ovsyannikova IG, Ryan JE et al. Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination. Clin Exp Immunol 2005;142: 498-504.
9. Howe RC, Dhiman N, Ovsyannikova IG, Poland GA. Induction of CD4 T cell proliferation and in vitro Th1-like cytokine responses to measles virus. Clin Exp Immunol 2005;140:333-42.
10. Ryan JE, Ovsyannikova IG, Poland GA. Detection of measles virus-specific interferon-gamma-secreting T-cells by ELISPOT. Methods Mol Biol 2005;302: 207-18.
11. Nanan R, Rauch A, Kämpgen E et al. A novel sensitive approach for frequency analysis of measles virus-specific memory T-lymphocytes in healthy adults with a childhood history of natural measles. J General Virol 2000;81:1313-9.
12. Beier D, Bigl S, Borte M et al. [Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen, E1 v. 01.01.2008]. http://www.slaek.de/60infos/36impfen/pdf/ e1.pdf
13. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
14. Berntson L, Wernroth L, Fasth A et al. Assessment of disease activity in juvenile idiopathic arthritis. The number and the size of joints matter. J Rheumatol 2007;34:2106-11.
15. Amine B, Rostom S, Benbouazza K et al. Health related quality of life survey about children and adolescents with juvenile idiopathic arthritis. Rheumatol Int. Advance Access published August 9, 2008, doi: 10.1007/s00296-008-0672-y.
16. Kreher CR, Dittrich MT, Guerkov R, Boehm BO, Tary-Lehmann M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 2003;278:79-93.
17. Millipore Corporation. IFN-γ Elispot Assays on MultiScreenb® IP. A Publication of Technical Services. Lit.No.: TN1003EN00. http://www.millipore.com/publications.nsf/docs/tn1003en00
18. Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA et al. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum 2007;56:639-46.
19. Kasapcopur O, Cullu F, Kamburoglu-Goksel A et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1128-30.
20. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001;19:589-94.
21. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005;54:273-80.
22. Yamaki K, Uchida H, Harada Y et al. Effect of methotrexate on Th1 and Th2 immune responses in mice. J Pharm Pharmacol 2003;55:1661-6.
23. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: A systematic review and critical analysis of the evidence. Clin Rheumatol 2008;27:67-76.
24. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66(Suppl. 3):iIi2-22.